Kane, JM, Aguglia, E, Altamura, AC, Ayuso-Gutierrez, JL, Brunello, N, Fleischhacker, WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol
1998; 8: 55–66.
Kane, JM, Quitkin, F, Rifkin, A, Ramos-Lorenzi, JR, Nayak, DV. Fluphenazine versus placebo in patients with remitted acute first episode schizophrenia. Arch Gen Psychiatry
1982; 39: 70–3.
Crow, TJ, MacMillan, JF, Johnson, AL, Johnstone, EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry
1986; 148: 120–7.
Robinson, DG, Woerner, MG, Delman, HM, Kane, JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull
2005; 31: 705–22.
Robinson, DG, Woerner, MG, Alvir, JMJ, Geisler, S, Koreen, A, Sheitman, B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry
1999; 156: 544–9.
Harding, CM, Zubin, J, Strauss, JS. Chronicity in schizophrenia: revisited. Br J Psychiatry
1992; 161 (suppl 18): 27–37.
Harrow, M, Jobe, TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15 year multifollow-up study. J Nerv Ment Dis
2007; 195: 406–14.
Kane, JM, Woerner, M, Weinhold, P, Wegner, J, Kinon, B. A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol
1982; 2: 345–9.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry
2004; 65: 267–73.
Lehman, AF, Steinwachs, DM, Survey Co-Investigators of the PORT Project. Patterns of usual care for schizophrenia. Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull
1998; 24: 11–20.
National Institute for Health and Clinical Excellence. Schizophrenia: Full National Clinical Guideline on Core Interventions in Primary and Secondary Care. Gaskell/British Psychological Society, 2003.
American Psychiatric Association Work Group on Schizophrenia. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry
2004; 161 (2 suppl): 1–56.
Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry
2005; 50 (suppl 1): 7S–56S.
Moore, TA, Buchanan, RW, Buckley, PF, Chiles, JA, Conley, RR, Crismon, ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry
2007; 68: 1751–62.
Miller, AL, Hall, CS, Buchanan, RW, Buckley, PF, Chiles, JA, Conley, RR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry
2004; 65: 500–8.
Argo, TR, Crismon, ML, Miller, AL, Moore, TA, Bendele, SD, Suehs, B. Texas Medication Algorithm Project Procedural Manual. Schizophrenia Treatment Algorithm. Texas Department of State Health Services, 2008.
Fenton, WS, Blyler, CR, Heinssen, RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull
1997; 23: 637–51.
Lacro, JP, Dunn, LB, Dolder, CR, Leckband, SG, Jeste, DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry
2002; 63: 892–907.
Velligan, DI, Lam, F, Ereshefsky, L, Miller, AL. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv
2003; 54: 665–7.
Velligan, DI, Wang, M, Diamond, P, Glahn, DC, Castillo, D, Bendle, S, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv
2007; 58: 1187–92.
Kane, JM, Rifkin, A, Quitkin, F, Nayak, D, Ramos-Lorenzi, J, Klein, DF, et al. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Res
1979; 1: 341–8.
Kane, JM, Rifkin, A, Woerner, M, Reardon, G, Sarantakos, S, Schiebel, D, et al. Low-dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates. Arch Gen Psychiatry
1983; 40: 893–6.
Schooler, NR, Keith, SJ, Severe, JB, Matthews, SM, Bellack, AS, Glick, ID, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. Arch Gen Psychiatry
1997; 54: 453–63.
Waddell, L, Taylor, M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry
2009; 195 (suppl 52): s43–50.
Gray, R, Spilling, R, Burgess, D, Newey, T. Long-acting injections in clinical practice: medication management and patient choice. Br J Psychiatry
2009; 195 (suppl 52): s51–6.
Emsley, R, Medori, R, Koen, L, Oosthuizen, PP, Niehaus, D, Rabinowitz, J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis. J Clin Psychopharm
2008; 28: 210–3.
Weiden, PJ, Schooler, NR, Weedon, JC, Elmouchtari, A, Sunakawa, A, Goldfinger, SM. Long-acting injectable risperidone vs. continuing on oral atypical antipsychotic for first-episode schizophrenia patients: initial adherence outcomes. J Clin Psychiatry